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Abstract We identified 11Lomentospora prolificans
isolates recovered from Mexican patients using phe-
notypic and molecular characteristics. The identifica-
tion of isolates was assessed by internal transcribed
spacer (ITS rDNA) sequencing. In vitro susceptibility
to amphotericin B, fluconazole, voriconazole,
posaconazole, caspofungin, anidulafungin and mica-
fungin was determined according to Clinical and
Laboratory Standards Institute (CLSI) procedures.
Three isolates (07-2239, 11-2242 and 04-2673) were
used to induce systemic infection in immunocompe-
tent ICRmice. Survival and tissue burden studies were
used as markers of pathogenicity. All of the strains
were resistant to every antifungal testedwithMIC’s for
AmB (8–[8 lg/ml), VRC (16–[16 lg/ml), PSC (16–
[16 lg/ml), FLC (64–[64 lg/ml) and echinocandins
with MICs C8 lg/ml. One hundred, ninety and sixty
percent of the infected mice with the strains 07-2239,
11-2242 and 04-2673 died during the study, respec-
tively. Regarding tissue burden, the highest fungal load
of the infected mice was detected in brain followed by
spleen and kidney, regardless of the strain.
Keywords Pathogenicity  In vitro susceptibility 
Survival study  Tissue burden  Lomentospora
prolificans
Introduction
Lomentospora prolificans (formerly Scedosporium
prolificans) [1] is an opportunistic filamentous mold;
it has a worldwide distribution and is frequently present
in soil, sewage and polluted waters. It is responsible for
serious infections due to its high virulence, propensity
for invasion, dissemination and multidrug resistance to
antifungals [2, 3]. Infections caused by this organism
can be localized, extended to the surrounding tissues or
disseminated to distant organs depending of the infec-
tion route and immunological status. When L. prolif-
icans infects immunocompetent individuals, usually
having a prior trauma in the form of puncture wounds,
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skin ulcers or surgery, it produces localized infections
that involve skin, bone and joints [4, 5]. In immuno-
compromised patients with cystic fibrosis, where the
most important risk factor for the acquisition of this
pathogen is inhalation and especially in those suffering
hematologic malignancies or organ-transplant recipi-
ents receiving immunosuppressive treatment, lesions
spread and they are usually fatal in less than a month.
Johnson et al. reported in 2014 that Scedosporiosis
(Scedosporium apiospermum/Lomentospora prolifi-
cans) followed lung transplantation in 55% of the cases
as well as other organ transplants (multivisceral, 18%;
heart, liver and small intestine in 45%). Scedosporiosis
was preceded by colonization in 36% of the reports.
Diseases included pneumonia (64%), mediastinitis
(18%) and fungemia/disseminated infections (18%)
[5, 6]. It is well documented that an altered immune
status of the host seems to be themain cause of invasion
by this mold, which mimics most of the pathologic
aspects of other opportunistic fungi such as Fusarium
spp., [7]Acremonium spp., [8] orAspergillus fumigatus
[9]. In these cases, the infection is probably acquired by
inhalation of conidia and the fungus is able to develop in
practically any body organ. On the other hand, L.
prolificans shows universal in vitro and in vivo resis-
tance to available antifungal drugs [5, 10–14] and
recovery from neutropenia has been considered a
mandatory prerequisite for resolving the infection
irrespective of the antifungal treatment used [10].
In this study, we identified 11 clinical isolates of L.
prolificans by morphological and molecular criteria.
Furthermore, we evaluated the pathogenicity of three
isolates of L. prolificans in an immunocompetent
murine model of disseminated infection.
Materials and Methods
Strains Identification
A total of 11 isolates collected over a period of
10 years (2003–2013) of L. prolificanswere recovered
from a broad spectrum of clinical presentations and
identified based on their macroscopic and microscopic
morphologies and ITS rDNA sequencing. Regarding
the phenotypic approach, clinical isolates were grown
at 30 C on potato dextrose agar (PDA) for 2 weeks.
For microscopic observation, slide cultures were made
and incubated at 30 C for 7 days. Carbohydrates
assimilation was determined for sucrose, L-arabinose,
lactose, D-ribose and maltose according to a method
previously described [15]. Hydrolysis of urea was
determined using Christensen’s urea agar which was
incubated at 30 C for 4 days, cycloheximide toler-
ance was determined by the isolates’ development on
Mycosel agar incubated at 30 C for 10 days, and the
gelatinase activity was assessed in gelatin agar slants
after 20 days at 30 C [16]. Aspartyl proteinase
activity was evaluated using bovine serum albumin
medium [17]. Phospholipase activity was carried out
on egg yolk medium [18]. Hemolytic activity was
assayed using Sabouraud blood medium [19]. In these
three last tests, plates were incubated at 30 C for
7 days and activity was expressed in terms of presence
or absence. Thermotolerance was studied by incubat-
ing the isolates on PDA for two weeks at 30, 37 and
40 C [16]. Candida albicans ATCC 90028 was used
as the quality control for all enzymatic activity
determinations.
In vitro susceptibility testing was performed by
the broth microdilution method for filamentous fungi
according to the CLSI document M38-A2 [20]. The
assayed antifungal agents were: amphotericin B
(AmB) (Bristol-Myers Squibb, Princeton, NJ), flu-
conazole (FLC) (Pfizer, Inc., New York, NY),
posaconazole (PSC) (Merck, Rahway, NJ) and
voriconazole (VRC) (Pfizer, Inc., New York, NY),
which were obtained as pure reagent-grade powders;
caspofungin (CSF), anidulafungin (ANF) and mica-
fungin (MCF) were purchased as Cancidas (Merck
Sharp & Dohme), Eraxis (Pfizer, Inc.) and Myca-
mine (Astellas Pharma, Inc.), respectively. The final
concentrations of the drugs ranged from 0.125 to
64 lg/ml for FLC, from 0.03 to 16 lg/ml for VRC,
PSC and AmB and from 0.015 to 8 lg/ml for
echinocandins. The microplates were incubated at
35 C for 72 h, and the MICs for all antifungals
were read visually. Amphotericin B, voriconazole
and posaconazole end points were determined as the
first clear well showing no growth, whereas flucona-
zole was read at C50% inhibition compared to the
control well. For echinocandins, MECs were deter-
mined microscopically as the lowest concentration
of drug promoting the growth of small, round,
compact hyphae relative to the appearance of the
filamentous forms seen in the control wells. Assays
were done in duplicate using Candida parapsilosis
ATCC 22019 and Paecilomyces variotii MYA 3630
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as quality control organisms. For in vitro suscepti-
bility testing, we determined the geometric mean
and range of MICs and MECs.
For ITS rDNA sequencing, the DNA of the isolates
was extracted using the method described by Gonza´lez
et al. [21]. Ribosomal DNA ITS domains were
amplified using the forward primer ITS-5 (50-
GGAAGTAAAAGTCGTAACAAGG-30) and reverse
primer ITS-4 (50-TCCTCCGCTTATTGATATGC-30)
[22]. Amplifications were performed in a final volume
of 30 ll containing 19 GoTaq Colorless Master Mix
(Promega, Madison, WI), 200 nM of each primer and
20 ng of DNA. The thermocycling conditions were:
94 C for 4 min, followed by 35 cycles of 94 C for
30 s, 53 C for 30 s and 72 C for 30 s, with final
extension at 72 C for 3 min. The final products were
electrophoresed in 1.5% agarose gels and stained with
SYBR Green I Gel Nucleic Acid Gel Stain (Invit-
rogenTM, Eugene, OR). HyperLadder I (Bioline USA
Inc.) was used as a molecular weight marker for size
determinations. The pattern of amplified bands was
photographed and analyzed with the UVP Bioimaging
System, EpiChemi III Darkroom. PCR products were
purified using the commercial Wizard SV Gel and
PCR Clean-Up system (Promega, Madison, WI).
Sequencing was performed utilizing the BigDye
Terminator v3.1 Cycle Sequencing kit (Applied
Biosystems, Foster city, CA) following the manufac-
turer’s directions. Reactions were run and analyzed in
an Avant 3100 Genetic Analyzer (Applied Biosys-
tems, Foster city, CA). For confirmation of phenotypic
identification, DNA sequence fragments were com-
pared to ISHAM-ITS database (http://its.
mycologylab.org/), Mycobank (http://mycobank.org/)
and NCBI GenBank, sequence entries using BLAST.
Identifications were made when BLAST searches
yielded C99% identity. The obtained sequences are
submitted to GenBank with the accession numbers
cited in Table 1.
Experimental Disseminated Infection
We established two different inocula based on our own
previous in vivo studies with the strain 07-2239 of L.
prolificans, comparing the mortality rate caused by
several inocula ranging from 103 to 106 conidia/animal
and where we observed that concentrations of 1 9 105
conidia/animal and 5 9 103 conidia/animal, caused a T
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100 and 50% mortality in 2 weeks, respectively (data
not shown).
The strains from different origins selected were
04-2673, 11-2242 and 07-2239 (sinusitis maxillaries
colonization, renal transplantation and acute myel-
ogenous leukemia) were cultured at least twice on
PDA plates to check the cultures purity and viability.
After 7 days of incubation at 30 C, conidial cells
were harvested and washed twice in sterile saline, and
the number of conidia in the suspensions was counted
with a hemocytometer and adjusted to the desired
concentration. To corroborate the conidial counts,
serial dilutions were cultured on PDA plates at 30 C.
Male ICR mice aged 4 weeks (weighing 20–22 g;
purchased from Harlan, Mexico) were used for the
in vivo studies. The animals were housed in cages of
five mice each. All mice were given food and water
ad libitum and were monitored daily. Care, mainte-
nance and handling of the animals were in accordance
with the Mexican government’s license conditions for
animal experimentation and the Guidelines for the
Care and Use of Laboratory Animals. Experiments
were conducted with the approval of the Ethics and
Research Committee of Facultad de Medicina, UANL
in Monterrey, Nuevo Leo´n, Mexico (registration code
MB11-008). No immunosuppressive scheme was
used.
For the survival study, we used ten mice for each
strain. Mice received an intravenous injection of
1 9 105 conidia/animal. Deaths were registered
through day 30 post-infection. Moribund mice were
killed, and deaths were recorded as occurring on the
next day. Animals that survived to day 30 were killed
by inhalation of metofane, followed by cervical
dislocation. The spleens and brains were removed
aseptically, homogenized separately in 2 ml of sterile
phosphate-buffered saline solution (138 mM NaCl,
3 mMKCl, 8.1 mMNa2HPO4 and 1.5 mM KH2PO4),
and the entire organs were plated onto PDA and
incubated at 30 C for 7 days to corroborate the
presence of fungi as the cause of death of the animals.
For the tissue burden study, 12 mice for each strain
received an intravenous injection of 5 9 103 conidia/
animal and groups of 4 mice per strain were sacrificed
on day 4, 7 and 10 post-infection. Half of kidneys,
spleens and brains of mice were assessed for fungal
burden bymeans of quantitative cultures, and the other
half of the organs were removed aseptically, weighed
and transferred to sterile glass homogenizers
containing 2 ml of sterile phosphate-buffered saline
solution (138 mM NaCl, 3 mM KCl, 8.1 mM Na2-
HPO4 and 1.5 mM KH2PO4). The organs were
mechanically homogenized (Polytron-Aggregate,
Kinematic), and serial tenfold dilutions of the suspen-
sions were plated onto PDA and incubated at 30 C for
7 days to determine the number of viable CFU in each
organ. Five uninfected mice were used as controls per
experimental day. The entire in vivo experiments were
performed twice at different times.
Histopathology
For the tissue burden study, after mice were killed,
tissues (half of each organ) were immediately
removed and fixed with 10% buffered formalin.
Samples were dehydrated, paraffin embedded and
sliced into 5-lm sections. The sections were stained
with Grocott methenamine silver for light microscopy
observations.
Statistics
Mean survival time (MST) was estimated by the
Kaplan–Meier method and compared among groups
by the log-rank test. The fungal tissue burdens of the
tested organs in the different experimental groups
were analyzed using the Kruskal–Wallis test in SPSS
(version 17.0 for Windows; Chicago, IL, USA) and
plotted using GraphPad Prism version 6.01 (Graph
Prism Software Inc., USA). P B 0.05 was statistically
significant.
Results
Demographic and Clinical Data
Eleven isolates of L. prolificans were registered at
Departamento de Microbiologı´a, Facultad de Medic-
ina, Universidad Auto´noma de Nuevo Leo´n, Monter-
rey, Mexico, from 2003 to 2013. The demographic
data of the patients are shown in Table 1. The median
age of the patients was 52 years with a range of
12–67 years. There were a total of six males (55%)
and five females (45%). Seven out of the eleven
patients had a hematologic malignancy and/or under-
went bone marrow or solid organ transplantation or
received long-term corticosteroids; this pathology was
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the most common underlying disease (64%) followed
by AIDS (18%). Three of these seven patients
developed fungemia. Nine out of 11 (82%) patients
died as a result of their underlying diseases associated
with their disseminated fungal infection. Colonization
of the respiratory tract was noted on one CF (fibrosis
cystic) patient and one with chronic sinusitis.
Strain Identification
The 11 isolates had colonial and microscopic charac-
teristics compatible with the genus Lomentospora. The
isolates grew on PDA plates at 30 C, reaching
55–65 mm after 2 weeks; the colonies were flat, with
short mycelium and olive gray to blackish in color.
Microscopic examination of slide cultures revealed
hyaline, septate hyphae. Conidiogenous cells were
flask shaped with single or multiple oval, smooth and
brown conidia at their tips. Results of physiologic
testing demonstrated that 100% of the isolates assim-
ilated L-arabinose, lactose and maltose, but none
assimilated sucrose and D-ribose. All isolates liquefied
gelatin, hydrolyzed urea and were producers of phos-
pholipase but none produced aspartyl proteinases or
hemolysins. Their growth was inhibited by the pres-
ence of cycloheximide on Mycosel agar. All isolates
grew at 30, 37, and 40 C. Based upon these features,
isolates were identified as L. prolificans [2] and further
confirmed by ITS (C99% ISHAM-ITS database) [22].
Antifungal Susceptibility
According to the MICs obtained, all the strains were
resistant to AmB (8[ 8 lg/ml), VRC (16–[16 lg/ml),
PSC (16–[16 lg/ml), FLC (64–[64 lg/ml). However,
echinocandins exhibited a moderate in vitro activity
against all strains when the minimum effective concen-
tration (MEC) was used as the end point for antifungal
susceptibility testing (MEC geometric mean 3.36, 4 and
4.36 lg/ml for ANF, MCF and CSF, respectively). The
MICs of the control strains were within the accept-
able range for the tested drugs (Table 2).
Experimental Disseminated Infection
The results confirmed the high virulence exhibited by
clinical strains of L. prolificans, since most of the
strains tested in the present study produced lethal
infections in all the mice (Fig. 1). One hundred
percent of the mice infected with strain 07-2239 and
90% of those infected with strain 11-2242 died
between 3–14 and 3–17 days, respectively. However,
a slight reduction in virulence was observed in the
mice infected with strain 04-2673, where animals died
between days 3 and 24 post-infection, with a 40%
survival at the end of the study. The mean survival
time (MST) in days for L. prolificans strains 07-2239,
11-2242 and 04-2673 with 95% confidence interval
(95% CI) was: 6.2 (4.18–8.22), 9.1 (4.11–14.08) and
17.8 (10.85–24.75), respectively (P\ 0.015). The
animals manifested a behavior consisting of running in
circles or gyrating by means of continuous lateral
rolling, ataxia, weight loss, ruffled hair and stiff neck
3 days before their death.
The fungal tissue burden results are summarized in
Table 3 and Fig. 2. In general, the highest fungal load
of all three strains was detected in brain followed by
Table 2 In vitro susceptibilities of 11 strains of L. prolificans
against seven antifungals
Strain/antifungal MIC/MEC 72 h (lg/mL)
Range GMa 50% 90%
L. prolificans (11)
Amphotericin B 16–[16 16 16 [16
Anidulafungin 2–8 3.36 2 8
Micafungin 1–8 4 4 8
Caspofungin 1–8 4.36 4 8
Voriconazole 16–[16 16 16 16
Posaconazole 16–[16 16 [16 [16
Fluconazole 64–[64 64 [64 [64
MIC minimum inhibitory concentration, MEC minimum
effective concentration
a Geometric mean
Fig. 1 Survival of mice infected with L. prolificans by
intravenous inoculation through the lateral vein with (1 9 105
conidia/mouse)
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spleen and kidney tested on the three experimental
days (P = 0.4283). No significant difference was
found between different strains or separate days. There
was a slight decrease in tissue burden during the days
7–10 of the experiments (P = 0.4156), and clearance
of the fungal elements was never observed in any
studied organs. Histopathological examination
revealed the presence polymorphonuclear cells infil-
tration, neurons presented morphological signs of
necrosis characterized by a hyperchromic and pyc-
notic nucleus, and abundant presence of hyphae and
conidia in all the brain tissue samples was taken from
the dissected mice during each of the three experi-
mental days (Fig. 3).
Discussion
Lomentospora prolificans can be considered as a truly
emerging dangerous pathogen; previous studies have
reported that it is associated with more severe
infections compared to those caused by other Sce-
dosporium species and the members of the Scedospo-
rium apiospermum species complex. Support for these
clinical finding has been demonstrated in previous
studies [26–30]. Rodrı´guez-Tudela et al. reported
patients with malignancies, disseminated infection
with L. prolificans was the most frequent (81.9%), and
it was associated with a high mortality rate 64%. This
is consistent with our results.
Table 3 Fungal tissue burden results in mice intravenously infected with inocula of 5 9 103 CFU/mouse
Strain (GenBank
accession number)
Organ Log CFU/g tissue [median (range)]
Days post-infection
4 7 10
L. prolificans
04-2673
(KJ176697)
Brain 4.70 (4.25–5.08) 3.65 (3.58–3.68) 3.81 (3.71–3.86)
Spleen 3.59 (3.49–3.88) 3.31 (3.12–3.46) 2.28 (2.22–2.44)
Kidney 2.70 (2.63–3.11) 2.59 (2.48–2.67) 2.11 (1.96–2.26)
07-2239
(KJ176701)
Brain 5.02 (4.73–5.07) 4.96 (5.40–4.60) 4.79 (4.67–5.95)
Spleen 3.75 (3.48–4.01) 3.51 (3.45–3.60) 3.22 (3.12–3.31)
Kidney 3.05 (2.99–3.14) 2.90 (2.85–2.95) 2.56 (2.45–2.82)
11-2242
(KJ176704)
Brain 4.88 (4.74–5.09) 4.73 (4.56–4.94) 4.71 (4.64–5.23)
Spleen 3.85 (3.68–3.95) 3.65 (3.55–3.66) 3.34 (3.08–3.54)
Kidney 3.10 (3.04–3.16) 2.98 (2.89–3.00) 2.55 (2.49–2.87)
Fig. 2 Graph of fungal
tissue burden results in mice
intravenously infected with
inocula of 5 9 103
CFU/mouse of the strains
tested by day 4, 7 and day 10
post-challenges
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Most of the patients receiving immunosuppressive
therapy developed fatal disseminated infection, and
nearly all of them underwent antifungal treatment,
however; the short survival period of most of the
patients with disseminated infections is alarming. One
of the most remarkable characteristics of the infections
caused by this mold is the high rate of positive blood
cultures, as reported previously especially in patients
with disseminated infections [26]. However, the
interpretation of these positive cultures is very difficult
and may lead to misinterpretation, and many of the
blood cultures didn’t turn positive until few days
before the death of the patient, thus limiting their
diagnostic utility [5]. Despite this mold being easily
identified once isolated, the mortality of disseminated
infections is so high that new procedures allowing a
more rapid diagnosis are required.
Breakthrough L. prolificans infections are fre-
quently found in patients with neutropenia under
antifungal prophylaxis [27]. This reflects the extreme
resistance of this species to these drugs in contrast to
other opportunistic hyphomycetes, e.g., P. boydii and
S. apiospermum. L. prolificans is known to be
multidrug resistant, especially to amphotericin B,
5-flucytosine, echinocandins and most azoles. While
there are limited data on the successful treatment of
patients with deep seated L. prolificans infection, the
combination of voriconazole and terbinafine appears to
be the most effective [28–30]. The resistance of L.
prolificans isolates to all antifungal in this study
suggests that there is a need for further studies on
susceptibility and resistance mechanisms of L. prolif-
icans. In general, our results correlatewith clinical data
because infections caused by these molds are usually
nonresponsive to antifungals and their outcomes are
usually fatal compared to S. apiospermum [10, 13, 30].
According to provisions in the guidelines of the
International Society for Human and Animal Mycol-
ogy (ISHAM)-ITS database, sequencing of this region
it is sufficient to reach an accurate identification of
these microorganisms [22]. The sequencing results
presented here confirm the high similarity within L.
Fig. 3 Representative histopathological Grocott methenamine
silver-stained sections of brain from ICR mice intravenously
infected with 5 9 103 CFU/mouse of the strains tested by days
4, 7 and day 10 post-challenge showing hyphal elements,
polymorphonuclear cell infiltration and signs of necrosis
characterized by a hyperchromic and pycnotic nucleus
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prolificans, which is known to be highly conserved at
the ITS region [31, 32].
A remarkable aspect of this study is that three of the
eleven strains tested exhibited virulence characteristics
which could be related to the pathology from which
they were isolated; the mildly virulent strain was
isolated from a sinusitis maxillaries colonization, and
the highly virulent strains were isolated from fatal
disseminated infections in patients with acute myel-
ogenous leukemia and renal transplantation, all in
Nuevo Leo´n, Me´xico. This could indicate that strains
with different virulence patterns can exist in the same
region, in agreement with Ortoneda et al. [23]. All L.
prolificans strains studied caused similar mortality
rates and tissues infiltration as shown by histopathol-
ogy examinations in the animals’ brains, spleens and
kidneys. These findings are consistent with results
from other authors [23–25], which confirms the
predilection of these fungi for brain tissues, being
more often reported in patients with disseminated
infections. The ability of L. prolificans to cause
invasive infection is also supported by its ability to
attack all visceral organs, particularly when it initiates
infection through intravenous route.
In conclusion, L. prolificans is a highly virulent
opportunistic fungus, as the clinical and experimental
data demonstrate. Due to the resistance of this fungus
to all available antifungal drugs, it is of enormous
importance to develop preventive strategies focusing
on reducing both environmental and host risk factors,
including decreasing the exposure of the airways and
reducing the risk associated with neutropenia.
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